Week 11 2025

Dr. Padma Sheila Rajagopal received her M.D. at Columbia University’s College of Physicians and Surgeons, during which she also received an M.P.H. in quantitative methods with a focus on genetic epidemiology at the Harvard School of Public Health. She completed her internal medicine residency training at the University of Pittsburgh and a fellowship in hematology/oncology with an additional fellowship year focused on cancer genetics at the University of Chicago, where she received an M.Sc. in biomedical informatics. Dr. Rajagopal is a recipient of the Ruth L. Kirschstein F32 Postdoctoral Fellowship and the American Society of Clinical Oncology / Breast Cancer Research Foundation Conquer Cancer Young Investigator Award.

Dr. Rajagopal’s laboratory focuses on how characterizing genomic and transcriptomic interactions between germline variants / inherited cancer syndromes and somatic development in tumors can improve clinical prediction and prognostication in patients with cancer. Her current research focuses on using transcriptomics to characterize breast cancers and treatment responses in patients with hereditary cancer syndromes.

STACY GRAY, MD, AM, is a Professor and Deputy Director for the Center for Precision Medicine, City of Hope Comprehensive Cancer Center and the Beckman Research Institute. She is also Chief of City of Hope Division Clinical Cancer Genomics, where she leads the clinical, research and educational initiatives of the program.  Dr. Gray's research is focused on realizing the promise of precision cancer medicine for all patients through translational genomics. The Gray lab focuses on improving access to genomic testing and targeted therapies, developing cancer prevention and screening strategies, eliminating care disparities, and rapidly translating innovative and effective new technologies into the clinic through interventions to improve the delivery of precision cancer medicine. Dr. Gray holds multiple leadership roles in a National Institutes of Health research consortium, and has a strong track record of research funding with support from the National Human Genome Research Institute, National Cancer Institute, Agency for Healthcare Research and Quality, American Cancer Society, and American Society of Clinical Oncology.

Kelly Bolton is a physician-scientist at Washington University in St. Louis. She is currently an assistant professor in the Section of Stem Cell Biology Division, Division of Oncology. Her research group focuses on utilizing genomic markers of cancer risk to develop prevention and early intervention strategies. Originally from Los Angeles, she completed her undergraduate studies at Cornell University. She completed medical school at the UCLA School of Medicine and a PhD in Genetic Epidemiology through Cambridge University. She went on to complete her residency in internal medicine and Cornell University and a fellowship in medical oncology at MSKCC. Her work has been published in high impact journals including Nature Genetics, JAMA, and JCO. She receives grant support from the National Cancer Institute, the EvansMDS foundation and the Damon Runyon Cancer Research Foundation

Bita Nehoray, MS, CGC, is a licensed board-certified genetic counselor specializing in cancer genetics. She received her Master’s degree in Human Genetics and Genetic Counseling from Stanford University. Ms. Nehoray joined the City of Hope Division of Clinical Cancer Genomics in 2012, where she provides cancer genetics services for patients and families suspected to have a hereditary predisposition to cancer, with a focus in Li-Fraumeni syndrome and clonal hematopoiesis of indeterminate potential. Current research projects include understanding cancer risk, penetrance, prevalence, and clinical outcomes for individuals with TP53 pathogenic variants as part of the LiFT UP study, evaluating the use of whole body MRI and liquid biopsy for early cancer detection, chatbot use for disclosure of germline genetic test results, and assessing community-based provider experiences with TP53 results on germline testing. She also serves on the genetic counseling advisory committee for the Li-Fraumeni Syndrome Association, the ClinGen TP53 Variant Curation Expert Panel, and the California Advisory Council for Sharsheret. She is faculty for the City of Hope Intensive Course in Genetic Cancer Risk Assessment. She is an active member of the National Society of Genetic Counselors and Southern California Genetic Counselors.